AUA 2017: Racial Disparities in Delivering Definitive Therapy for Intermediate-High Risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics

Boston, MA (UroToday.com) African American populations are reported to be at an increased risk for high-grade, high-volume prostate cancer, (PC) with its attendant impact on prostate cancer specific mortality. Dr. David F. Friedlander reports a population-based study, suggesting that the disparity may be due to a lower rate of definitive therapy.

283,153 men (n= 59,262 African American and n=223,873 Caucasian) diagnosed with high-risk PC between January 2002 and December 2013 were identified in the National Cancer Database. All men were >40 years of age, with biopsy-confirmed localized intermediate to high risk PC. Sensitivity and subgroup analyses were performed to adjust for inherent patient and facility-level differences.

RESULTS: 82.9% (n¼185,647) of White men received definitive therapy compared to 73.7% (n¼43,662) of Black men over a 10- year period. Overall rates of definitive therapy during that time increased for both White (81.3% vs. 83.3%, p)

Authors: David F. Friedlander, Nicolas von Landenberg, Philipp Gild, Quoc-Dien Trinh, Patrick Karabon, Maxine Sun, Paul L. Nguyen, Adam S. Kibel, Toni K. Choueiri, Joel S. Weissman, Mani Menon, Firas Abdollah

Presented by: David F. Friedlander (MD) of Brigham and Women's Hospital

Written By: Linda Huynh (BS), an assistant research specialist from the University of California, Irvine, on behalf of UroToday.com

at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA